

Sujata Patil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11329535/publications.pdf>

Version: 2024-02-01

165
papers

9,970
citations

36691

53
h-index

46524

93
g-index

167
all docs

167
docs citations

167
times ranked

13965
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 957-966.	5.1	524
2	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. <i>Clinical Cancer Research</i> , 2011, 17, 5132-5139.	3.2	396
3	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 3379-3384.	0.8	370
4	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-5059.	3.2	338
5	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	15.2	320
6	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.	0.8	298
7	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	0.8	292
8	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2010, 28, 3762-3769.	0.8	283
9	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	13.7	233
10	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	0.7	232
11	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	0.8	192
12	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6784-6791.	3.2	176
13	Long-term Renal Outcomes after Cisplatin Treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1173-1179.	2.2	155
14	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2015, 33, 3945-3952.	0.8	153
15	Impact of Breast Density on the Presenting Features of Malignancy. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-218.	0.7	141
16	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
17	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
18	Identifying Vulnerable Older Adults with Cancer: Integrating Geriatric Assessment into Oncology Practice. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1604-1608.	1.3	131

#	ARTICLE	IF	CITATIONS
19	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. <i>Clinical Cancer Research</i> , 2011, 17, 3490-3499.	3.2	131
20	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3154-3159.	0.8	121
21	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121
22	Distress in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4346-4351.	0.8	116
23	Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1146-1155.	0.7	115
24	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	2.0	109
25	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 147-153.	0.7	100
26	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 22-27.	0.7	99
27	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96
28	Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 813-823.	1.9	95
29	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. <i>Annals of Surgery</i> , 2015, 262, 623-631.	2.1	94
30	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
31	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	1.1	91
32	Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. <i>Clinical Breast Cancer</i> , 2017, 17, 23-28.	1.1	91
33	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. <i>Annals of Surgery</i> , 2017, 266, 457-462.	2.1	90
34	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
35	Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. <i>Cancer</i> , 2012, 118, 1664-1674.	2.0	81
36	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2012, 118, 1982-1988.	2.0	80

#	ARTICLE	IF	CITATIONS
37	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	1.2	79
38	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. <i>Cancer</i> , 2011, 117, 5461-5468.	2.0	77
39	Selection Criteria for Postmastectomy Radiotherapy in T1â€“T2 Tumors with 1 to 3 Positive Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2013, 20, 3169-3174.	0.7	77
40	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77
41	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 442-447.	0.8	75
42	Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. <i>Health Affairs</i> , 2017, 36, 274-281.	2.5	75
43	Estrogen Receptor, Progesterone Receptor, and HER2 Status Predict Lymphovascular Invasion and Lymph Node Involvement. <i>Annals of Surgical Oncology</i> , 2014, 21, 3780-3786.	0.7	71
44	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	0.8	70
45	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2548-2555.	0.7	70
46	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
47	Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. <i>Journal of the American College of Surgeons</i> , 2016, 222, 138-145.	0.2	68
48	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	1.2	66
49	A Randomized Prospective Comparison of Patientâ€“Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. <i>Breast Journal</i> , 2016, 22, 151-157.	0.4	65
50	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1797-1802.	0.8	60
51	Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 407-416.	1.1	56
52	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012, 118, 5454-5462.	2.0	55
53	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. <i>Cancer Medicine</i> , 2013, 2, 725-733.	1.3	54
54	Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms. <i>JAMA Network Open</i> , 2020, 3, e200681.	2.8	54

#	ARTICLE	IF	CITATIONS
55	Is there a role for routine screening MRI in women with LCIS?. Breast Cancer Research and Treatment, 2013, 142, 445-453.	1.1	53
56	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. Cancer, 2012, 118, 981-986.	2.0	50
57	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. Annals of Surgical Oncology, 2014, 21, 1552-1560.	0.7	50
58	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment, 2011, 129, 635-643.	1.1	49
59	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Over	1.0	49
60	Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?. Annals of Surgical Oncology, 2017, 24, 1492-1498.	0.7	47
61	Stage migration and increasing proportion of favorable prognosis metastatic renal cell carcinoma patients. Cancer, 2010, 116, 347-354.	2.0	46
62	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 297-302.	0.9	46
63	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2015, 22, 3273-3281.	0.7	46
64	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist, 2016, 21, 418-424.	1.9	46
65	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nature Communications, 2020, 11, 319.	5.8	46
66	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2017, 24, 2556-2562.	0.7	45
67	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	2.2	45
68	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	3.2	45
69	Twenty-one gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	2.0	42
70	Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer. European Journal of Radiology, 2016, 85, 1651-1658.	1.2	42
71	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	1.1	42
72	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research, 2019, 25, 3784-3792.	3.2	41

#	ARTICLE	IF	CITATIONS
73	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
74	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Caseâ€“Control Study. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 897-902.	0.7	41
75	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. <i>Annals of Surgery</i> , 2010, 251, 583-591.	2.1	40
76	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. <i>Journal of Clinical Oncology</i> , 2010, 28, 2982-2988.	0.8	40
77	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. <i>Annals of Surgical Oncology</i> , 2016, 23, 4253-4261.	0.7	40
78	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 685-692.	0.7	40
79	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
80	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. <i>Annals of Surgical Oncology</i> , 2016, 23, 2816-2824.	0.7	38
81	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	1.1	37
82	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1912-1920.	0.7	37
83	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. <i>Cancer</i> , 2018, 124, 46-54.	2.0	37
84	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
85	Fertility Preservation for the Young Breast Cancer Patient. <i>Annals of Surgical Oncology</i> , 2016, 23, 1530-1536.	0.7	35
86	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 93-102.	1.1	34
87	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	0.6	34
88	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	0.9	32
89	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
90	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	2.0	30

#	ARTICLE	IF	CITATIONS
91	Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2182-2188.	0.7	30
92	Logistic Regression in Clinical Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 271-277.	0.4	30
93	Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. <i>Breast Journal</i> , 2012, 18, 345-350.	0.4	29
94	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
95	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2889-2897.	0.7	28
96	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017, 22, 139-143.	1.9	27
97	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 3481-3486.	0.7	25
98	Carboplatin in Clinical Stage I Seminoma: Too Much and Too Little at the Same Time. <i>Journal of Clinical Oncology</i> , 2011, 29, 949-952.	0.8	23
99	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
100	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
101	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1463-1470.	0.7	22
102	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
103	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	1.2	21
104	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 111-116.	1.1	21
105	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017, 7, 32-37.	1.0	21
106	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 800-807.	0.9	21
107	Phase II Trial of Pegylated Interferon- β 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	0.9	20
108	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	0.7	20

#	ARTICLE	IF	CITATIONS
109	Early Trastuzumab Interruption and Recurrence-Free Survival in <i>ERBB2</i> -Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1971.	3.4	20
110	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. <i>Cancer</i> , 2009, 115, 1203-1214.	2.0	19
111	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.	2.3	19
112	Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. <i>Cancer</i> , 2013, 119, 3943-3951.	2.0	18
113	Should Breast Density Influence Patient Selection for Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2013, 20, 600-606.	0.7	17
114	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	0.8	17
115	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade + [~] trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
116	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. <i>Cancer</i> , 2011, 117, 4125-4131.	2.0	16
117	Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?. <i>Cancer</i> , 2017, 123, 2626-2633.	2.0	16
118	Breast carcinoma with an Oncotype Dx recurrence score ≤ 18: Rate of distant metastases in a large series with clinical follow-up. <i>Cancer</i> , 2017, 123, 131-137.	2.0	16
119	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. <i>Clinical Breast Cancer</i> , 2018, 18, 353-361.	1.1	16
120	Comparative analysis of the Memorial Sloan Kettering Bowel Function Instrument and the Low Anterior Resection Syndrome Questionnaire for assessment of bowel dysfunction in rectal cancer patients after low anterior resection. <i>Colorectal Disease</i> , 2021, 23, 451-460.	0.7	16
121	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
122	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	3.2	15
123	Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 487-493.	1.1	13
124	Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 471-476.	0.7	13
125	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3888-3895.	0.7	13
126	Measuring Tumor Epichaperome Expression Using [¹²⁴ I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1414-1424.	1.5	13

#	ARTICLE	IF	CITATIONS
127	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
128	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
129	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
130	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. <i>Clinical Breast Cancer</i> , 2016, 16, 276-283.	1.1	11
131	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
132	Endoscopic Feature and Response Reproducibility in Tumor Assessment after Neoadjuvant Therapy for Rectal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 5205-5223.	0.7	11
133	Work Experiences of Patients Receiving Palliative Care at a Comprehensive Cancer Center: Exploratory Analysis. <i>Journal of Palliative Medicine</i> , 2017, 20, 770-773.	0.6	10
134	Single Nucleotide Polymorphism TGF β 21 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 924-930.	0.4	10
135	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7) Tj ETQq1 1 0.784314 rgBT /Overl 2.3 9	0.7	10
136	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	2.3	9
137	Brain metastases in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 173-183.	1.1	8
138	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
139	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2012, 30, 3143-3144.	0.8	7
140	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1302-1310.	0.7	7
141	Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer?. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 193-198.	0.7	7
142	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
143	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2 α Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	2.8	7
144	Comprehensive Genomic Analysis of Metastatic Non α Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7

#	ARTICLE	IF	CITATIONS
145	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 45-52.	0.7	7
146	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6
147	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	2.1	6
148	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. <i>BJS Open</i> , 2021, 5, .	0.7	6
149	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	0.9	5
150	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	1.9	5
151	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
152	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	2.1	3
153	Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10618-10618.	0.8	3
154	Reply to C. Mazouni et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e45-e46.	0.8	2
155	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	0.9	2
156	Vulnerabilities in workplace features for essential workers with breast cancer: Implications for the COVID-19 pandemic. <i>Work</i> , 2022, 71, 815-823.	0.6	2
157	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. <i>Colorectal Disease</i> , 2022, 24, 1318-1324.	0.7	2
158	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 87-94.	1.1	1
159	Use of patient-reported controls for secular trends to study disparities in cancer-related job loss. <i>Journal of Cancer Survivorship</i> , 2020, 15, 685-695.	1.5	1
160	Interpreting the RAPIDO trial: factors to consider. <i>Lancet Oncology</i> , The, 2021, 22, e87-e88.	5.1	1
161	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 144-144.	0.8	1
162	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.. <i>Journal of Clinical Oncology</i> , 2015, 33, 32-32.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Reply to S. Stenning et al and J. Lipshitz. Journal of Clinical Oncology, 2011, 29, 4211-4212.	0.8	0
164	Targeted Oligonucleotide Array Assessment of Genomic Copy Number Alterations for Risk Stratification in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1773-1773.	0.6	0
165	Lymphedema therapy referral is associated with improved understanding of lymphedema prevention among breast cancer survivors.. Journal of Clinical Oncology, 2022, 40, 12069-12069.	0.8	0